Health Care Supplies

Nexgel

Nexgel released FY2026 Q1 earnings on May 14 Pre-Market (EST), actual revenue USD 2.65 M (forecast USD 3.909 M), actual EPS USD -0.1129 (forecast USD -0.07)

Nexgel to Release FY2026 Q1 Earnings on May 15 Pre-Market EST, Forecast Revenue USD 3.909 M, EPS USD -0.07

Nexgel released FY2025 earnings on March 31 After-Market (EST), actual revenue USD 11.42 M (forecast USD 11.86 M), actual EPS USD -0.3819 (forecast USD -0.35)

Nexgel released FY2025 Q4 earnings on March 31 After-Market EST, actual revenue USD 2.796 M (forecast USD 3.24 M), actual EPS USD -0.1206 (forecast USD -0.09)

Nexgel to Release FY2025 Q4 Earnings on March 31 After-Market EST, Forecast Revenue USD 3.24 M, EPS USD -0.09

Nexgel Splits Off Drug Delivery Unit as NexGelRx

Maxim Group Analyst Reiterates Buy Rating on NexGel Inc

Nexgel released FY2025 9 Months Earnings on November 12 After-Market EST, Actual Revenue: USD 8.624 M, Actual EPS: USD -0.265

Nexgel released FY2025 Q3 earnings on November 12 After-Market EST, actual revenue USD 2.934 M (forecast USD 3.164 M), actual EPS USD -0.0819 (forecast USD -0.08)

Nexgel to release FY2025 Q3 earnings on November 11 After-Market EST, forecast revenue USD 3.164 M, EPS USD -0.08

Nexgel released FY2025 Q2 earnings on August 12 After-Market (EST), actual revenue USD 2.884 M (forecast USD 3.08 M), actual EPS USD -0.0899 (forecast USD -0.07)

Nexgel released FY2025 Semi-Annual earnings on August 12 After-Market EST, actual revenue USD 5.69 M, actual EPS USD -0.18

Nexgel to Release FY2025 Q2 Earnings on August 12 After-Market (EST), Forecast Revenue USD 3.08M, EPS USD -0.07

NEXGEL Announces Expansion of Collaboration with STADA Arzneimittel

Nexgel CEO Reports Disposition of Common Stock

Director of Nexgel Inc. Disposes of Common Stock

Nexgel released FY2025 Q1 earnings on May 13 After-Market EST: Actual Revenue USD 2.806 M (Forecast USD 2.725 M), Actual EPS USD -0.0931 (Forecast USD -0.1)

Nexgel Inc narrows quarterly loss per share, revenue surges

NEXGEL to Release Q1 2025 Financial Results

Nexgel to Release FY2025 Q1 Earnings on May 13 After-Market EST, Forecast Revenue USD 2.725 M, EPS USD -0.1

InMed Pharmaceuticals

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Amesite

CN Energy

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NextNRG

Meiwu Tech

Generation Income Properties

MetaVia

OceanPal

NXGL

LABU

SBIO

NEXGEL shares are trading higher after the company announced data from randomized, 30-patient, single-center Institutional Review Board clinical study.

benzinga_article

iShares Biotechnology ETF

Invesco Biotechnology & Genome ETF

SPDR S&P Health Equip

SPDR S&P Biotech

Proshares Ultra Nasdaq Biotech

VanEck Biotech ETF

Direxion S&P Biotech Bull 3X

ALPS Medical Breakthrough

iShares US Medical Devices

First Trust NYSE Arca Biotech Index Fd

NEXGEL INC C/WTS 27/12/2026 (TO PUR COM)

NexGel raised $1.21 million through a private placement of unsecured convertible notes and warrants, with a conversion price of $0.60 per share and a warrant exercise price of $0.80. The funds will support working capital, with a significant portion purchased by affiliates. NexGel also agreed to register the resale of underlying shares, enhancing investor liquidity.

TradingView

NexGel Raises $1.21 Million Via Convertible Notes and Warrants; $0.60 Conversion, $0.80 Exercise

NexGel (NASDAQ:NXGL) reported Q1 2026 revenue of $2.65 million, down from $2.81 million last year, mainly due to lower Silly George sales. The company acquired BioNx, expected to triple annual revenue to $35 million. NexGel raised $13.8 million for the acquisition, including a $5 million convertible note. A strategic partnership with Sequence Life Science was formed, investing $5.5 million. New appointments include Dave Hazard as VP of Sales and Ian Blackman as CFO. NexGel plans to update on integration and financial performance in August.

Celularity

Celularity - CW26

NexGel Q1 2026 Earnings Call Transcript

Earnings Watch

Nexgel | 10-Q: FY2026 Q1 Revenue Misses Estimate at USD 2.65 M

NEXGEL, Inc. (NASDAQ: NXGL) will report its first quarter 2026 financial results on May 15, 2026, and host a conference call at 12:00 P.M. ET. The call will be accessible via U.S. and international numbers, with a replay available until May 29, 2026. NEXGEL specializes in healthcare and beauty products, particularly high-water-content hydrogel products. The company has been in the industry for over two decades and has established strategic partnerships with leading consumer healthcare companies.

StockTitan

NEXGEL To Report First Quarter 2026 Financial Results on May 15th | NXGL Stock News

NexGel, Inc. received a deficiency notice from Nasdaq due to its stock trading below the $1.00 minimum bid price for 30 consecutive business days, violating Nasdaq Listing Rule 5550(a)(2). The company has 180 days to regain compliance or face potential delisting. NexGel may consider a reverse stock split to meet requirements. Currently, the stock is rated as a Buy with a $2.00 price target, but analysts express concerns over weak financial performance and risks associated with future financing and integration.

Tip Ranks

Nasdaq

NexGel Receives Nasdaq Deficiency Notice Over Bid Price